It looks like you are using an older version of Internet Explorer which is not supported. We advise that you update your browser to the latest version of Microsoft Edge, or consider using other browsers such as Chrome, Firefox or Safari.

Why was ZARXIO prescribed for me?

Some cancer treatments decrease white blood cell counts, which may weaken the immune system and increase the risk of infection. This is a condition known as neutropenia.

ZARXIO is a man-made form of granulocyte colony-stimulating factor (G-CSF) called filgrastim. The purpose of G-CSF is to stimulate the growth of neutrophils, a type of white blood cell that is important in the body's fight against infection. ZARXIO is used to reduce the risk of infection in patients with some tumors who are receiving strong chemotherapy that may cause severe neutropenia with fever.

What is a biosimilar?

A biosimilar is a medication that has been approved by the FDA as being “highly similar” to a previously approved biologic medication. Biosimilars may be available at a lower cost than the referenced biologic medication. ZARXIO is the first biosimilar approved in the US.

ZARXIO Patient Brochure


ZARXIO Patient Brochure

ZARXIO Patient Brochure (Spanish)


References: 1. Patel K, West H. Febrile Neutropenia. JAMA Oncol. 2017;3(12):1751. doi10.1001/jamaoncol.2017.1114 2. ZARXIO Prescribing Information. Sandoz Inc. September 2022. 3. Socal M, Ballreich, Chyr L, Anderson G, for the Johns Hopkins Bloomberg School of Public Health. Biosimilar medications—savings opportunities for large employers. March 2020. 4. Fierce Pharma. FDA approves first biosimilar product Zarxio. Accessed February 13, 2023.